Large-scale testing (Phase 3)Looking for participantsNCT07005102
What this trial is testing
Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
AbbVie 854